Mark D. Long

This study identifies M1C as a driver of sotorasib resistance in NSCLC KRAS G12C mutant tumors and shows that targeting M1C improves treatment outcomes.

This paper identifies HNF1A as a BRD4 target and shows that BET-inhibitors' antitumor effects in PDAC depend on HNF1A ablation.

This study shows M1C is necessary for daraxonrasib resistance in NSCLC KRAS(G12C) mutant cells and identifies M1C as a potential therapeutic target.

This study shows RB1 loss in EGFR mutant lung cancer leads to reversible lineage plasticity, accelerating resistance to EGFR TKI therapy through non-genetic mechanisms.

This study identifies HNF1A as an oncogenic driver of PDAC metastasis through upregulation of FGFR4 and shows that FGFR4 inhibition reduces metastasis in vitro and in vivo.

This study shows that blocking p38 reduces metastasis in breast cancer by reversing immune suppression in the tumor microenvironment, primarily through effects on CD8+ T cells and myeloid cells.

This study identifies RARγ's role in bookmarking AR enhancer interactions in prostate cancer, showing its impact on enzalutamide sensitivity and lineage plasticity.

The paper analyzes metabolic dysregulation across 26 cancer types using TCGA data to identify pathway-specific changes and their clinical implications.